| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 170 | 2023 | 773 | 37.620 |
Why?
|
| Homosexuality, Male | 122 | 2023 | 298 | 28.310 |
Why?
|
| Pre-Exposure Prophylaxis | 52 | 2023 | 137 | 19.250 |
Why?
|
| Sexual and Gender Minorities | 51 | 2023 | 192 | 12.710 |
Why?
|
| Anti-HIV Agents | 28 | 2023 | 149 | 10.730 |
Why?
|
| Social Networking | 39 | 2023 | 75 | 10.480 |
Why?
|
| Sexual Behavior | 56 | 2023 | 302 | 9.200 |
Why?
|
| Chicago | 64 | 2023 | 1378 | 5.830 |
Why?
|
| Social Support | 25 | 2020 | 193 | 5.680 |
Why?
|
| Transgender Persons | 14 | 2022 | 95 | 5.450 |
Why?
|
| Risk-Taking | 35 | 2021 | 148 | 4.960 |
Why?
|
| Contact Tracing | 12 | 2023 | 29 | 4.720 |
Why?
|
| Young Adult | 104 | 2023 | 5961 | 4.630 |
Why?
|
| Syphilis | 8 | 2023 | 27 | 4.420 |
Why?
|
| Disease Transmission, Infectious | 11 | 2019 | 57 | 4.260 |
Why?
|
| Medication Adherence | 11 | 2022 | 123 | 4.080 |
Why?
|
| Male | 183 | 2023 | 40652 | 3.920 |
Why?
|
| Patient Acceptance of Health Care | 16 | 2020 | 238 | 3.840 |
Why?
|
| Sexual Partners | 23 | 2023 | 93 | 3.800 |
Why?
|
| Sexually Transmitted Diseases | 14 | 2023 | 91 | 3.690 |
Why?
|
| Unsafe Sex | 17 | 2023 | 42 | 3.640 |
Why?
|
| Adolescent | 84 | 2023 | 8959 | 3.410 |
Why?
|
| Adult | 142 | 2023 | 25518 | 3.410 |
Why?
|
| Health Knowledge, Attitudes, Practice | 24 | 2021 | 500 | 3.390 |
Why?
|
| Continuity of Patient Care | 9 | 2021 | 168 | 3.130 |
Why?
|
| Humans | 224 | 2023 | 85777 | 2.980 |
Why?
|
| Residence Characteristics | 10 | 2020 | 193 | 2.820 |
Why?
|
| Social Stigma | 11 | 2021 | 52 | 2.570 |
Why?
|
| HIV-1 | 8 | 2021 | 164 | 2.480 |
Why?
|
| Safe Sex | 7 | 2020 | 23 | 2.310 |
Why?
|
| Substance-Related Disorders | 10 | 2023 | 394 | 2.290 |
Why?
|
| Health Promotion | 10 | 2020 | 149 | 2.280 |
Why?
|
| Criminals | 3 | 2020 | 33 | 2.060 |
Why?
|
| HIV Seropositivity | 8 | 2020 | 49 | 1.970 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2023 | 78 | 1.930 |
Why?
|
| Viral Load | 10 | 2020 | 150 | 1.920 |
Why?
|
| Papillomavirus Infections | 7 | 2022 | 239 | 1.870 |
Why?
|
| Internet | 7 | 2021 | 311 | 1.680 |
Why?
|
| Female | 81 | 2023 | 44216 | 1.650 |
Why?
|
| Peer Group | 6 | 2021 | 72 | 1.640 |
Why?
|
| Circumcision, Male | 5 | 2013 | 18 | 1.640 |
Why?
|
| Health Status Disparities | 6 | 2020 | 170 | 1.570 |
Why?
|
| India | 17 | 2018 | 120 | 1.530 |
Why?
|
| Socioeconomic Factors | 15 | 2020 | 561 | 1.510 |
Why?
|
| Automobile Driving | 5 | 2014 | 31 | 1.480 |
Why?
|
| Referral and Consultation | 6 | 2021 | 325 | 1.460 |
Why?
|
| Logistic Models | 17 | 2020 | 1179 | 1.430 |
Why?
|
| Criminal Law | 4 | 2021 | 11 | 1.400 |
Why?
|
| Social Media | 4 | 2020 | 79 | 1.360 |
Why?
|
| United States | 32 | 2023 | 6580 | 1.340 |
Why?
|
| Condoms | 7 | 2019 | 36 | 1.330 |
Why?
|
| Risk Factors | 24 | 2023 | 5249 | 1.320 |
Why?
|
| Middle Aged | 54 | 2022 | 24740 | 1.250 |
Why?
|
| Longitudinal Studies | 15 | 2020 | 1015 | 1.240 |
Why?
|
| Anus Neoplasms | 3 | 2019 | 30 | 1.240 |
Why?
|
| Cohort Studies | 18 | 2023 | 2738 | 1.220 |
Why?
|
| Cross-Sectional Studies | 20 | 2023 | 1604 | 1.180 |
Why?
|
| Substance Abuse, Intravenous | 7 | 2021 | 54 | 1.170 |
Why?
|
| Opioid-Related Disorders | 8 | 2022 | 159 | 1.160 |
Why?
|
| Cell Phone | 4 | 2018 | 37 | 1.160 |
Why?
|
| HIV Seronegativity | 3 | 2020 | 12 | 1.160 |
Why?
|
| Stress, Psychological | 6 | 2021 | 313 | 1.090 |
Why?
|
| Crime | 3 | 2020 | 36 | 1.060 |
Why?
|
| Prevalence | 16 | 2022 | 1210 | 1.060 |
Why?
|
| Health Services Accessibility | 8 | 2022 | 393 | 1.050 |
Why?
|
| Motor Vehicles | 4 | 2012 | 18 | 1.050 |
Why?
|
| Family Relations | 2 | 2016 | 35 | 1.020 |
Why?
|
| Incidence | 12 | 2022 | 1543 | 0.980 |
Why?
|
| Coinfection | 3 | 2022 | 58 | 0.970 |
Why?
|
| HIV | 8 | 2022 | 46 | 0.960 |
Why?
|
| Cannabis | 2 | 2023 | 33 | 0.960 |
Why?
|
| Violence | 2 | 2018 | 142 | 0.950 |
Why?
|
| Health Surveys | 8 | 2019 | 236 | 0.910 |
Why?
|
| Herpes Genitalis | 3 | 2015 | 41 | 0.900 |
Why?
|
| Hand Disinfection | 2 | 2021 | 17 | 0.900 |
Why?
|
| Papillomaviridae | 4 | 2022 | 153 | 0.880 |
Why?
|
| Skin Pigmentation | 3 | 2022 | 40 | 0.880 |
Why?
|
| Surveys and Questionnaires | 19 | 2022 | 2500 | 0.870 |
Why?
|
| Social Capital | 2 | 2021 | 3 | 0.840 |
Why?
|
| Social Work | 2 | 2019 | 19 | 0.830 |
Why?
|
| Urban Population | 5 | 2018 | 214 | 0.810 |
Why?
|
| Viremia | 1 | 2021 | 55 | 0.810 |
Why?
|
| Sexuality | 1 | 2021 | 40 | 0.800 |
Why?
|
| Masks | 1 | 2021 | 29 | 0.800 |
Why?
|
| Ambulatory Care Facilities | 3 | 2020 | 103 | 0.790 |
Why?
|
| Travel | 2 | 2018 | 68 | 0.790 |
Why?
|
| Emergency Service, Hospital | 4 | 2023 | 484 | 0.790 |
Why?
|
| Interpersonal Relations | 4 | 2020 | 171 | 0.790 |
Why?
|
| Motivation | 4 | 2019 | 287 | 0.790 |
Why?
|
| Anus Diseases | 2 | 2022 | 15 | 0.780 |
Why?
|
| Racism | 3 | 2019 | 81 | 0.780 |
Why?
|
| Risk Assessment | 7 | 2020 | 2213 | 0.770 |
Why?
|
| Sleep Wake Disorders | 1 | 2022 | 114 | 0.770 |
Why?
|
| Electronic Health Records | 5 | 2023 | 320 | 0.740 |
Why?
|
| Bisexuality | 6 | 2020 | 32 | 0.740 |
Why?
|
| Drug Prescriptions | 2 | 2020 | 140 | 0.730 |
Why?
|
| Resilience, Psychological | 1 | 2020 | 23 | 0.730 |
Why?
|
| Primary Prevention | 1 | 2020 | 78 | 0.720 |
Why?
|
| Exposure to Violence | 2 | 2018 | 12 | 0.710 |
Why?
|
| Healthcare Disparities | 5 | 2019 | 372 | 0.690 |
Why?
|
| Epidemics | 2 | 2018 | 33 | 0.680 |
Why?
|
| Delivery of Health Care | 3 | 2019 | 422 | 0.670 |
Why?
|
| Health Behavior | 4 | 2021 | 182 | 0.670 |
Why?
|
| Texas | 7 | 2022 | 101 | 0.660 |
Why?
|
| Sex Workers | 2 | 2021 | 9 | 0.660 |
Why?
|
| Heterosexuality | 1 | 2018 | 17 | 0.650 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2017 | 61 | 0.650 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 50 | 0.650 |
Why?
|
| Patient Compliance | 4 | 2021 | 220 | 0.650 |
Why?
|
| Gender Identity | 3 | 2023 | 52 | 0.640 |
Why?
|
| Mass Screening | 7 | 2021 | 601 | 0.630 |
Why?
|
| Models, Psychological | 2 | 2016 | 157 | 0.630 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 59 | 0.630 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 378 | 0.620 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 21 | 0.620 |
Why?
|
| Reproductive Health | 1 | 2018 | 32 | 0.610 |
Why?
|
| Greece | 8 | 2022 | 17 | 0.600 |
Why?
|
| Text Messaging | 2 | 2015 | 27 | 0.600 |
Why?
|
| Uncertainty | 1 | 2017 | 71 | 0.590 |
Why?
|
| Anti-Retroviral Agents | 4 | 2018 | 30 | 0.590 |
Why?
|
| Louisiana | 4 | 2020 | 17 | 0.590 |
Why?
|
| Penile Neoplasms | 1 | 2016 | 10 | 0.580 |
Why?
|
| Health Status | 3 | 2019 | 360 | 0.580 |
Why?
|
| Marijuana Use | 1 | 2016 | 6 | 0.570 |
Why?
|
| Rural Population | 6 | 2023 | 136 | 0.560 |
Why?
|
| Health Care Reform | 1 | 2017 | 86 | 0.550 |
Why?
|
| Tenofovir | 3 | 2022 | 7 | 0.550 |
Why?
|
| Urban Health | 2 | 2013 | 54 | 0.540 |
Why?
|
| Communication | 2 | 2019 | 440 | 0.540 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 26 | 0.530 |
Why?
|
| Psychoanalytic Therapy | 1 | 2015 | 3 | 0.530 |
Why?
|
| Psychoanalytic Theory | 1 | 2015 | 9 | 0.530 |
Why?
|
| Group Processes | 1 | 2015 | 31 | 0.520 |
Why?
|
| Chemoprevention | 1 | 2015 | 92 | 0.520 |
Why?
|
| Thinking | 1 | 2015 | 33 | 0.510 |
Why?
|
| Social Identification | 1 | 2015 | 24 | 0.510 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 118 | 0.510 |
Why?
|
| Bias | 2 | 2020 | 127 | 0.500 |
Why?
|
| Sociometric Techniques | 1 | 2014 | 3 | 0.490 |
Why?
|
| Self Disclosure | 1 | 2014 | 31 | 0.490 |
Why?
|
| Spinal Injuries | 1 | 2014 | 20 | 0.490 |
Why?
|
| Multiple Trauma | 1 | 2014 | 31 | 0.490 |
Why?
|
| Women's Health | 1 | 2015 | 100 | 0.490 |
Why?
|
| Electronic Mail | 1 | 2014 | 14 | 0.480 |
Why?
|
| Quality Improvement | 2 | 2017 | 426 | 0.480 |
Why?
|
| Patient Participation | 1 | 2016 | 215 | 0.480 |
Why?
|
| Transportation | 3 | 2013 | 18 | 0.480 |
Why?
|
| Complementary Therapies | 1 | 2014 | 54 | 0.470 |
Why?
|
| Cervical Vertebrae | 1 | 2014 | 79 | 0.470 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 275 | 0.470 |
Why?
|
| Restaurants | 1 | 2013 | 5 | 0.460 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2014 | 91 | 0.460 |
Why?
|
| Interviews as Topic | 6 | 2019 | 318 | 0.460 |
Why?
|
| Mexican Americans | 1 | 2013 | 63 | 0.450 |
Why?
|
| Multivariate Analysis | 5 | 2021 | 985 | 0.450 |
Why?
|
| Comorbidity | 5 | 2023 | 912 | 0.440 |
Why?
|
| Decision Making | 2 | 2016 | 643 | 0.440 |
Why?
|
| Friends | 1 | 2012 | 17 | 0.420 |
Why?
|
| Seroepidemiologic Studies | 4 | 2019 | 55 | 0.420 |
Why?
|
| Marriage | 1 | 2012 | 25 | 0.420 |
Why?
|
| Depression | 1 | 2016 | 472 | 0.420 |
Why?
|
| Pandemics | 6 | 2022 | 737 | 0.400 |
Why?
|
| Perception | 4 | 2020 | 168 | 0.400 |
Why?
|
| Video Recording | 1 | 2012 | 190 | 0.400 |
Why?
|
| Drug Users | 3 | 2021 | 19 | 0.400 |
Why?
|
| Aged | 13 | 2021 | 18161 | 0.390 |
Why?
|
| Counseling | 1 | 2012 | 145 | 0.390 |
Why?
|
| Quality of Health Care | 4 | 2017 | 379 | 0.380 |
Why?
|
| Prisoners | 2 | 2023 | 40 | 0.380 |
Why?
|
| Retrospective Studies | 6 | 2021 | 8456 | 0.380 |
Why?
|
| Population Dynamics | 1 | 2011 | 130 | 0.380 |
Why?
|
| Risk Reduction Behavior | 4 | 2018 | 92 | 0.370 |
Why?
|
| Drug Overdose | 2 | 2022 | 65 | 0.370 |
Why?
|
| Central Nervous System Stimulants | 2 | 2023 | 215 | 0.360 |
Why?
|
| Health Services Research | 2 | 2008 | 136 | 0.360 |
Why?
|
| Self Efficacy | 2 | 2022 | 53 | 0.350 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 90 | 0.350 |
Why?
|
| Cities | 5 | 2022 | 40 | 0.340 |
Why?
|
| Poverty | 2 | 2021 | 173 | 0.340 |
Why?
|
| Hygiene | 1 | 2009 | 10 | 0.340 |
Why?
|
| Age Factors | 3 | 2018 | 1828 | 0.330 |
Why?
|
| Nitrites | 2 | 2018 | 30 | 0.330 |
Why?
|
| AIDS Serodiagnosis | 2 | 2020 | 25 | 0.320 |
Why?
|
| Minority Groups | 2 | 2022 | 137 | 0.320 |
Why?
|
| Male Urogenital Diseases | 1 | 2007 | 9 | 0.310 |
Why?
|
| Insurance, Health | 2 | 2020 | 156 | 0.310 |
Why?
|
| Gingiva | 1 | 2007 | 8 | 0.310 |
Why?
|
| Alcoholism | 2 | 2020 | 172 | 0.310 |
Why?
|
| AIDS Vaccines | 1 | 2007 | 10 | 0.310 |
Why?
|
| Female Urogenital Diseases | 1 | 2007 | 9 | 0.310 |
Why?
|
| HIV Antibodies | 1 | 2007 | 26 | 0.310 |
Why?
|
| Rural Health | 1 | 2007 | 20 | 0.310 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 64 | 0.310 |
Why?
|
| Sex Work | 3 | 2018 | 12 | 0.310 |
Why?
|
| Trust | 3 | 2023 | 96 | 0.310 |
Why?
|
| Cervix Uteri | 1 | 2007 | 65 | 0.310 |
Why?
|
| Schools | 2 | 2021 | 71 | 0.300 |
Why?
|
| France | 7 | 2019 | 47 | 0.290 |
Why?
|
| Pilot Projects | 2 | 2021 | 832 | 0.290 |
Why?
|
| Gift Giving | 1 | 2006 | 5 | 0.290 |
Why?
|
| Odds Ratio | 5 | 2018 | 676 | 0.280 |
Why?
|
| Illinois | 4 | 2020 | 462 | 0.280 |
Why?
|
| Community-Based Participatory Research | 2 | 2020 | 35 | 0.280 |
Why?
|
| Drug Industry | 1 | 2006 | 53 | 0.270 |
Why?
|
| Sex Factors | 3 | 2020 | 1041 | 0.270 |
Why?
|
| Social Perception | 1 | 2006 | 95 | 0.260 |
Why?
|
| Geography | 2 | 2021 | 223 | 0.260 |
Why?
|
| Analgesics, Opioid | 4 | 2023 | 412 | 0.260 |
Why?
|
| Patient-Centered Care | 2 | 2019 | 203 | 0.260 |
Why?
|
| Cluster Analysis | 3 | 2021 | 368 | 0.260 |
Why?
|
| Alcohol Drinking | 2 | 2019 | 264 | 0.260 |
Why?
|
| Phylogeny | 6 | 2020 | 1137 | 0.250 |
Why?
|
| HIV Seroprevalence | 2 | 2018 | 9 | 0.250 |
Why?
|
| Attitude | 3 | 2022 | 127 | 0.250 |
Why?
|
| Models, Theoretical | 5 | 2021 | 482 | 0.240 |
Why?
|
| Hospitals, Rural | 1 | 2004 | 5 | 0.240 |
Why?
|
| Time Factors | 4 | 2019 | 5178 | 0.240 |
Why?
|
| Ethics, Medical | 1 | 2006 | 306 | 0.230 |
Why?
|
| Occupational Health | 2 | 2014 | 32 | 0.230 |
Why?
|
| Health Risk Behaviors | 2 | 2020 | 5 | 0.230 |
Why?
|
| Anal Canal | 3 | 2022 | 89 | 0.220 |
Why?
|
| Otolaryngology | 3 | 2016 | 53 | 0.220 |
Why?
|
| Sexual Health | 1 | 2023 | 14 | 0.220 |
Why?
|
| Patient Transfer | 1 | 2004 | 91 | 0.220 |
Why?
|
| Herpesvirus 2, Human | 2 | 2015 | 45 | 0.220 |
Why?
|
| Smartphone | 3 | 2019 | 36 | 0.220 |
Why?
|
| Internal Medicine | 1 | 2006 | 348 | 0.210 |
Why?
|
| Quality Indicators, Health Care | 1 | 2004 | 145 | 0.210 |
Why?
|
| Vulnerable Populations | 2 | 2020 | 76 | 0.210 |
Why?
|
| Geographic Information Systems | 2 | 2019 | 20 | 0.210 |
Why?
|
| Program Evaluation | 2 | 2014 | 290 | 0.210 |
Why?
|
| Infectious Disease Medicine | 1 | 2021 | 7 | 0.210 |
Why?
|
| Data Collection | 2 | 2014 | 372 | 0.200 |
Why?
|
| Capacity Building | 1 | 2021 | 10 | 0.200 |
Why?
|
| Rhinitis | 2 | 2017 | 175 | 0.200 |
Why?
|
| Human papillomavirus 18 | 2 | 2022 | 16 | 0.200 |
Why?
|
| Public Health | 3 | 2022 | 129 | 0.200 |
Why?
|
| Prospective Studies | 4 | 2023 | 4160 | 0.190 |
Why?
|
| Human papillomavirus 16 | 2 | 2022 | 38 | 0.190 |
Why?
|
| Emtricitabine | 1 | 2020 | 2 | 0.190 |
Why?
|
| San Francisco | 1 | 2020 | 21 | 0.190 |
Why?
|
| Sinusitis | 2 | 2017 | 210 | 0.190 |
Why?
|
| DNA, Viral | 2 | 2018 | 265 | 0.190 |
Why?
|
| Health Education | 2 | 2019 | 99 | 0.190 |
Why?
|
| Probability | 1 | 2021 | 352 | 0.190 |
Why?
|
| Rural Health Services | 1 | 2020 | 13 | 0.190 |
Why?
|
| Natural Language Processing | 1 | 2021 | 37 | 0.190 |
Why?
|
| Mentoring | 1 | 2021 | 30 | 0.190 |
Why?
|
| Intensive Care Units | 1 | 2004 | 374 | 0.190 |
Why?
|
| Social Norms | 1 | 2019 | 9 | 0.180 |
Why?
|
| Psychological Theory | 1 | 2020 | 22 | 0.180 |
Why?
|
| Psychotherapy, Brief | 1 | 2020 | 10 | 0.180 |
Why?
|
| Universities | 2 | 2019 | 135 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2020 | 7830 | 0.180 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 54 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 3591 | 0.180 |
Why?
|
| Marijuana Smoking | 2 | 2018 | 29 | 0.180 |
Why?
|
| Atherosclerosis | 2 | 2020 | 240 | 0.180 |
Why?
|
| Forecasting | 1 | 2020 | 301 | 0.170 |
Why?
|
| Eligibility Determination | 1 | 2019 | 32 | 0.170 |
Why?
|
| Public Health Practice | 1 | 2019 | 11 | 0.170 |
Why?
|
| Cooperative Behavior | 2 | 2019 | 173 | 0.170 |
Why?
|
| Patient Navigation | 1 | 2019 | 12 | 0.170 |
Why?
|
| Housing | 1 | 2019 | 42 | 0.170 |
Why?
|
| Professional-Patient Relations | 1 | 2019 | 52 | 0.170 |
Why?
|
| Health Expenditures | 1 | 2020 | 86 | 0.170 |
Why?
|
| Community Health Centers | 1 | 2020 | 113 | 0.170 |
Why?
|
| Awareness | 1 | 2019 | 88 | 0.170 |
Why?
|
| Geographic Mapping | 1 | 2018 | 12 | 0.160 |
Why?
|
| Equipment Design | 2 | 2018 | 405 | 0.160 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2018 | 23 | 0.160 |
Why?
|
| Population Surveillance | 1 | 2020 | 214 | 0.160 |
Why?
|
| Truth Disclosure | 1 | 2019 | 87 | 0.160 |
Why?
|
| Organizational Affiliation | 1 | 2018 | 6 | 0.160 |
Why?
|
| Sex Distribution | 1 | 2018 | 170 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 853 | 0.160 |
Why?
|
| Demography | 1 | 2018 | 177 | 0.160 |
Why?
|
| China | 2 | 2009 | 227 | 0.160 |
Why?
|
| Sleep | 1 | 2022 | 441 | 0.160 |
Why?
|
| Unemployment | 1 | 2017 | 8 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 451 | 0.160 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 2 | 0.160 |
Why?
|
| Models, Statistical | 3 | 2019 | 574 | 0.160 |
Why?
|
| Personhood | 1 | 2017 | 17 | 0.150 |
Why?
|
| Police | 1 | 2017 | 23 | 0.150 |
Why?
|
| Health Services Administration | 1 | 2017 | 2 | 0.150 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 44 | 0.150 |
Why?
|
| Financing, Organized | 1 | 2017 | 12 | 0.150 |
Why?
|
| Qualitative Research | 2 | 2022 | 256 | 0.150 |
Why?
|
| Health Equity | 1 | 2019 | 77 | 0.150 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2380 | 0.150 |
Why?
|
| Papillomavirus Vaccines | 1 | 2017 | 58 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2006 | 1011 | 0.150 |
Why?
|
| Personal Satisfaction | 1 | 2017 | 62 | 0.150 |
Why?
|
| Community Health Services | 1 | 2018 | 77 | 0.140 |
Why?
|
| Genotype | 2 | 2018 | 1848 | 0.140 |
Why?
|
| Focus Groups | 2 | 2019 | 155 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 66 | 0.140 |
Why?
|
| Marijuana Abuse | 1 | 2016 | 26 | 0.140 |
Why?
|
| Hepatitis C | 1 | 2019 | 210 | 0.140 |
Why?
|
| Cues | 1 | 2017 | 175 | 0.140 |
Why?
|
| Likelihood Functions | 1 | 2016 | 251 | 0.140 |
Why?
|
| Cocaine-Related Disorders | 1 | 2016 | 34 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2017 | 117 | 0.140 |
Why?
|
| Physician-Patient Relations | 2 | 2016 | 610 | 0.140 |
Why?
|
| Transsexualism | 1 | 2016 | 34 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 578 | 0.130 |
Why?
|
| Reimbursement, Incentive | 1 | 2016 | 37 | 0.130 |
Why?
|
| Vaccination | 1 | 2017 | 256 | 0.130 |
Why?
|
| Medicaid | 1 | 2018 | 217 | 0.130 |
Why?
|
| Crime Victims | 1 | 2016 | 34 | 0.130 |
Why?
|
| Instinct | 1 | 2015 | 2 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2019 | 755 | 0.130 |
Why?
|
| Psychotherapy, Group | 1 | 2015 | 33 | 0.130 |
Why?
|
| Treponema pallidum | 1 | 2015 | 8 | 0.130 |
Why?
|
| Bayes Theorem | 1 | 2016 | 360 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 395 | 0.130 |
Why?
|
| Paris | 3 | 2019 | 5 | 0.130 |
Why?
|
| Ukraine | 3 | 2019 | 14 | 0.130 |
Why?
|
| Medicare | 1 | 2018 | 408 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2016 | 153 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 141 | 0.130 |
Why?
|
| Atlanto-Occipital Joint | 1 | 2014 | 3 | 0.120 |
Why?
|
| Trauma, Nervous System | 1 | 2014 | 5 | 0.120 |
Why?
|
| Atlanto-Axial Joint | 1 | 2014 | 8 | 0.120 |
Why?
|
| Trauma Severity Indices | 1 | 2014 | 42 | 0.120 |
Why?
|
| Ligaments, Articular | 1 | 2014 | 36 | 0.120 |
Why?
|
| Health Services | 2 | 2019 | 55 | 0.120 |
Why?
|
| Thoracic Vertebrae | 1 | 2014 | 49 | 0.120 |
Why?
|
| Causality | 1 | 2014 | 78 | 0.120 |
Why?
|
| Cognition | 1 | 2019 | 570 | 0.120 |
Why?
|
| Community Participation | 1 | 2014 | 36 | 0.120 |
Why?
|
| Craniocerebral Trauma | 1 | 2014 | 52 | 0.120 |
Why?
|
| Albuterol | 1 | 2014 | 35 | 0.120 |
Why?
|
| Delphi Technique | 1 | 2013 | 80 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 129 | 0.120 |
Why?
|
| Bronchodilator Agents | 1 | 2014 | 65 | 0.120 |
Why?
|
| Lactic Acid | 1 | 2014 | 90 | 0.120 |
Why?
|
| Trauma Centers | 1 | 2014 | 115 | 0.120 |
Why?
|
| Spinal Fusion | 1 | 2014 | 85 | 0.110 |
Why?
|
| Drama | 1 | 2013 | 7 | 0.110 |
Why?
|
| Joint Instability | 1 | 2014 | 80 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1989 | 0.110 |
Why?
|
| Quality of Life | 2 | 2020 | 1581 | 0.110 |
Why?
|
| Occupations | 1 | 2012 | 26 | 0.110 |
Why?
|
| Telephone | 1 | 2012 | 32 | 0.110 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2012 | 10 | 0.110 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2012 | 24 | 0.110 |
Why?
|
| Leadership | 1 | 2014 | 131 | 0.110 |
Why?
|
| Prejudice | 1 | 2012 | 48 | 0.100 |
Why?
|
| Spouses | 1 | 2012 | 33 | 0.100 |
Why?
|
| Child | 2 | 2020 | 6930 | 0.100 |
Why?
|
| Molecular Sequence Data | 1 | 2016 | 3034 | 0.100 |
Why?
|
| Tracheostomy | 1 | 2012 | 42 | 0.100 |
Why?
|
| Extramarital Relations | 1 | 2011 | 1 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2012 | 283 | 0.100 |
Why?
|
| Coitus | 1 | 2011 | 20 | 0.100 |
Why?
|
| Marital Status | 1 | 2011 | 40 | 0.100 |
Why?
|
| Social Class | 1 | 2012 | 128 | 0.100 |
Why?
|
| Epidemiologic Research Design | 1 | 2011 | 22 | 0.100 |
Why?
|
| Sodium, Dietary | 1 | 2011 | 8 | 0.100 |
Why?
|
| Hyponatremia | 1 | 2011 | 25 | 0.100 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 239 | 0.100 |
Why?
|
| Health Care Coalitions | 1 | 2011 | 9 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2012 | 218 | 0.100 |
Why?
|
| Length of Stay | 1 | 2014 | 704 | 0.100 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 29 | 0.100 |
Why?
|
| Occupational Diseases | 1 | 2011 | 55 | 0.090 |
Why?
|
| Registries | 1 | 2014 | 701 | 0.090 |
Why?
|
| Pediatrics | 1 | 2014 | 344 | 0.090 |
Why?
|
| Women's Health Services | 1 | 2009 | 14 | 0.090 |
Why?
|
| Sodium | 1 | 2011 | 328 | 0.090 |
Why?
|
| Public Sector | 1 | 2009 | 12 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 342 | 0.090 |
Why?
|
| Molecular Epidemiology | 2 | 2020 | 53 | 0.090 |
Why?
|
| New York City | 2 | 2020 | 59 | 0.080 |
Why?
|
| HIV Serosorting | 2 | 2018 | 3 | 0.080 |
Why?
|
| Social Environment | 2 | 2020 | 188 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 812 | 0.080 |
Why?
|
| Vaginal Discharge | 1 | 2007 | 2 | 0.080 |
Why?
|
| Warts | 1 | 2007 | 11 | 0.080 |
Why?
|
| Diet | 1 | 2011 | 438 | 0.080 |
Why?
|
| Ulcer | 1 | 2007 | 36 | 0.080 |
Why?
|
| Therapeutic Irrigation | 1 | 2007 | 60 | 0.080 |
Why?
|
| Machine Learning | 2 | 2020 | 232 | 0.080 |
Why?
|
| Infant | 1 | 2014 | 3049 | 0.080 |
Why?
|
| Hospitals, University | 1 | 2008 | 194 | 0.080 |
Why?
|
| Mucous Membrane | 1 | 2007 | 83 | 0.080 |
Why?
|
| Immunoglobulin A | 1 | 2007 | 80 | 0.080 |
Why?
|
| Physicians | 1 | 2014 | 672 | 0.070 |
Why?
|
| Conflict of Interest | 1 | 2006 | 67 | 0.070 |
Why?
|
| Vitamin D | 1 | 2008 | 260 | 0.070 |
Why?
|
| Hospitalization | 3 | 2022 | 830 | 0.070 |
Why?
|
| Research Design | 2 | 2020 | 580 | 0.070 |
Why?
|
| Asthma | 1 | 2014 | 955 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 457 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2007 | 901 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 121 | 0.070 |
Why?
|
| Pain | 1 | 2007 | 387 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 1 | 2004 | 112 | 0.060 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2004 | 8 | 0.060 |
Why?
|
| Iowa | 1 | 2004 | 35 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6479 | 0.060 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 27 | 0.060 |
Why?
|
| Hospitals, Community | 1 | 2004 | 32 | 0.060 |
Why?
|
| Pheochromocytoma | 1 | 2004 | 48 | 0.060 |
Why?
|
| Patient Admission | 1 | 2004 | 111 | 0.060 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2004 | 78 | 0.060 |
Why?
|
| Parental Consent | 1 | 2023 | 35 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1804 | 0.060 |
Why?
|
| Neoplasms | 1 | 2017 | 2895 | 0.050 |
Why?
|
| Employment | 1 | 2022 | 52 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3366 | 0.050 |
Why?
|
| Naloxone | 1 | 2022 | 59 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 34 | 0.050 |
Why?
|
| Case Management | 1 | 2021 | 24 | 0.050 |
Why?
|
| Lost to Follow-Up | 1 | 2021 | 12 | 0.050 |
Why?
|
| Needle Sharing | 1 | 2020 | 14 | 0.050 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 1 | 0.050 |
Why?
|
| Informed Consent | 1 | 2023 | 266 | 0.050 |
Why?
|
| Parents | 1 | 2023 | 272 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2013 | 593 | 0.040 |
Why?
|
| Florida | 1 | 2019 | 55 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 3 | 0.040 |
Why?
|
| New Orleans | 1 | 2019 | 6 | 0.040 |
Why?
|
| Africa | 1 | 2019 | 98 | 0.040 |
Why?
|
| Homophobia | 1 | 2019 | 4 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 39 | 0.040 |
Why?
|
| Knowledge | 1 | 2019 | 29 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 674 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 304 | 0.040 |
Why?
|
| Europe, Eastern | 1 | 2018 | 3 | 0.040 |
Why?
|
| Mouth | 1 | 2018 | 48 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 67 | 0.040 |
Why?
|
| New York | 1 | 2018 | 69 | 0.040 |
Why?
|
| Penis | 1 | 2018 | 56 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 68 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 94 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 668 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 154 | 0.040 |
Why?
|
| Economic Competition | 1 | 2017 | 12 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2018 | 63 | 0.040 |
Why?
|
| Interinstitutional Relations | 1 | 2017 | 28 | 0.040 |
Why?
|
| Exercise | 1 | 2020 | 309 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 657 | 0.040 |
Why?
|
| London | 1 | 2016 | 16 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 71 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2015 | 34 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 2015 | 37 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 232 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 456 | 0.030 |
Why?
|
| Algorithms | 1 | 2023 | 1824 | 0.030 |
Why?
|
| Family | 1 | 2016 | 311 | 0.030 |
Why?
|
| Ipratropium | 1 | 2014 | 18 | 0.030 |
Why?
|
| Spirometry | 1 | 2014 | 66 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 539 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 122 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 258 | 0.030 |
Why?
|
| Self Report | 1 | 2014 | 288 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 420 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 136 | 0.030 |
Why?
|
| Safety Management | 1 | 2012 | 56 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 787 | 0.030 |
Why?
|
| Animals | 1 | 2011 | 26650 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2012 | 64 | 0.030 |
Why?
|
| Pressure | 1 | 2012 | 165 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 350 | 0.020 |
Why?
|
| Middle East | 1 | 2011 | 17 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 278 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 27 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2011 | 45 | 0.020 |
Why?
|
| Software | 1 | 2014 | 653 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 223 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1696 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 397 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1458 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2012 | 335 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 153 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1697 | 0.020 |
Why?
|
| Mobile Health Units | 1 | 2007 | 11 | 0.020 |
Why?
|
| Tracheotomy | 1 | 2007 | 18 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 632 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2008 | 930 | 0.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 104 | 0.010 |
Why?
|
| Inflammation | 1 | 2008 | 922 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 827 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2004 | 315 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 2899 | 0.010 |
Why?
|